244 related articles for article (PubMed ID: 30970628)
1. The Potential Role of iNOS in Ovarian Cancer Progression and Chemoresistance.
Kielbik M; Szulc-Kielbik I; Klink M
Int J Mol Sci; 2019 Apr; 20(7):. PubMed ID: 30970628
[TBL] [Abstract][Full Text] [Related]
2. Increased intracellular Ca
Yu Y; Xie Q; Liu W; Guo Y; Xu N; Xu L; Liu S; Li S; Xu Y; Sun L
Biomed Pharmacother; 2017 Feb; 86():8-15. PubMed ID: 27936394
[TBL] [Abstract][Full Text] [Related]
3. The role of oxidative stress in the development of cisplatin resistance in epithelial ovarian cancer.
Belotte J; Fletcher NM; Awonuga AO; Alexis M; Abu-Soud HM; Saed MG; Diamond MP; Saed GM
Reprod Sci; 2014 Apr; 21(4):503-8. PubMed ID: 24077440
[TBL] [Abstract][Full Text] [Related]
4. The homeoprotein DLX4 controls inducible nitric oxide synthase-mediated angiogenesis in ovarian cancer.
Trinh B; Ko SY; Haria D; Barengo N; Naora H
Mol Cancer; 2015 Apr; 14():97. PubMed ID: 25924901
[TBL] [Abstract][Full Text] [Related]
5. Myeloperoxidase serves as a redox switch that regulates apoptosis in epithelial ovarian cancer.
Saed GM; Ali-Fehmi R; Jiang ZL; Fletcher NM; Diamond MP; Abu-Soud HM; Munkarah AR
Gynecol Oncol; 2010 Feb; 116(2):276-81. PubMed ID: 19962178
[TBL] [Abstract][Full Text] [Related]
6. Production of nitric oxide and expression of inducible nitric oxide synthase in ovarian cystic tumors.
Nomelini RS; de Abreu Ribeiro LC; Tavares-Murta BM; Adad SJ; Murta EF
Mediators Inflamm; 2008; 2008():186584. PubMed ID: 19132106
[TBL] [Abstract][Full Text] [Related]
7. The role and prognostic value of inducible nitric oxide synthase (iNOS) and interleukin-33 (IL-33) in serous and mucinous epithelial ovarian tumours.
Saied EM; El-Etreby NM
Ann Diagn Pathol; 2017 Apr; 27():62-68. PubMed ID: 28325363
[TBL] [Abstract][Full Text] [Related]
8. High nitric oxide production, secondary to inducible nitric oxide synthase expression, is essential for regulation of the tumour-initiating properties of colon cancer stem cells.
Puglisi MA; Cenciarelli C; Tesori V; Cappellari M; Martini M; Di Francesco AM; Giorda E; Carsetti R; Ricci-Vitiani L; Gasbarrini A
J Pathol; 2015 Aug; 236(4):479-90. PubMed ID: 25875314
[TBL] [Abstract][Full Text] [Related]
9. iNOS-derived nitric oxide promotes glycolysis by inducing pyruvate kinase M2 nuclear translocation in ovarian cancer.
Li L; Zhu L; Hao B; Gao W; Wang Q; Li K; Wang M; Huang M; Liu Z; Yang Q; Li X; Zhong Z; Huang W; Xiao G; Xu Y; Yao K; Liu Q
Oncotarget; 2017 May; 8(20):33047-33063. PubMed ID: 28380434
[TBL] [Abstract][Full Text] [Related]
10. Inducible NO synthase confers chemoresistance in head and neck cancer by modulating survivin.
Fetz V; Bier C; Habtemichael N; Schuon R; Schweitzer A; Kunkel M; Engels K; Kovács AF; Schneider S; Mann W; Stauber RH; Knauer SK
Int J Cancer; 2009 May; 124(9):2033-41. PubMed ID: 19130609
[TBL] [Abstract][Full Text] [Related]
11. NO signaling confers cytoprotectivity through the survivin network in ovarian carcinomas.
Engels K; Knauer SK; Loibl S; Fetz V; Harter P; Schweitzer A; Fisseler-Eckhoff A; Kommoss F; Hanker L; Nekljudova V; Hermanns I; Kleinert H; Mann W; du Bois A; Stauber RH
Cancer Res; 2008 Jul; 68(13):5159-66. PubMed ID: 18593915
[TBL] [Abstract][Full Text] [Related]
12. Nitric Oxide Generated by Tumor-Associated Macrophages Is Responsible for Cancer Resistance to Cisplatin and Correlated With Syntaxin 4 and Acid Sphingomyelinase Inhibition.
Perrotta C; Cervia D; Di Renzo I; Moscheni C; Bassi MT; Campana L; Martelli C; Catalani E; Giovarelli M; Zecchini S; Coazzoli M; Capobianco A; Ottobrini L; Lucignani G; Rosa P; Rovere-Querini P; De Palma C; Clementi E
Front Immunol; 2018; 9():1186. PubMed ID: 29896202
[TBL] [Abstract][Full Text] [Related]
13. Transcriptional regulation of inducible nitric oxide synthase gene therapy: targeting early stage and advanced prostate cancer.
Coulter JA; Page NL; Worthington J; Robson T; Hirst DG; McCarthy HO
J Gene Med; 2010 Sep; 12(9):755-65. PubMed ID: 20821746
[TBL] [Abstract][Full Text] [Related]
14. Relevance of iNOS expression in tumor growth and maintenance of cancer stem cells in a bladder cancer model.
Belgorosky D; Girouard J; Langle YV; Hamelin-Morrissete J; Marino L; Agüero EI; Malagrino H; Reyes-Moreno C; Eiján AM
J Mol Med (Berl); 2020 Nov; 98(11):1615-1627. PubMed ID: 32955679
[TBL] [Abstract][Full Text] [Related]
15. Cisplatin alters nitric oxide synthase levels in human ovarian cancer cells: involvement in p53 regulation and cisplatin resistance.
Leung EL; Fraser M; Fiscus RR; Tsang BK
Br J Cancer; 2008 Jun; 98(11):1803-9. PubMed ID: 18506185
[TBL] [Abstract][Full Text] [Related]
16. Lipopolysaccharide causes NFĸB-mediated induction of inducible nitric oxide synthase gene and more production of nitric oxide in air-breathing catfish, Clarias magur (Hamilton).
Choudhury MG; Kumari S; Das KB; Saha N
Gene; 2018 Jun; 658():18-27. PubMed ID: 29524573
[TBL] [Abstract][Full Text] [Related]
17. MircroRNA-139 sensitizes ovarian cancer cell to cisplatin-based chemotherapy through regulation of ATP7A/B.
Xiao F; Li Y; Wan Y; Xue M
Cancer Chemother Pharmacol; 2018 May; 81(5):935-947. PubMed ID: 29594361
[TBL] [Abstract][Full Text] [Related]
18. Upregulation of programmed death ligand-1 in tumor-associated macrophages affects chemotherapeutic response in ovarian cancer cells.
Jang YS; Kim TW; Ryu JS; Kong HJ; Jang SH; Nam GH; Kim JH; Jeon S
PLoS One; 2023; 18(2):e0277285. PubMed ID: 36757936
[TBL] [Abstract][Full Text] [Related]
19. Identifying novel hypoxia-associated markers of chemoresistance in ovarian cancer.
McEvoy LM; O'Toole SA; Spillane CD; Martin CM; Gallagher MF; Stordal B; Blackshields G; Sheils O; O'Leary JJ
BMC Cancer; 2015 Jul; 15():547. PubMed ID: 26205780
[TBL] [Abstract][Full Text] [Related]
20. NPM-ALK up-regulates iNOS expression through a STAT3/microRNA-26a-dependent mechanism.
Zhu H; Vishwamitra D; Curry CV; Manshouri R; Diao L; Khan A; Amin HM
J Pathol; 2013 May; 230(1):82-94. PubMed ID: 23338972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
